© Wolf G Kroner 2018 l-r Hugues Vaussy, Bruno Poddevin, Berthold Hackl, Gilles Martin, Eurofins Eurofins: Dealing with Corruption Risks, Compliance,
and Value Management

December 2018. Global analytical and medical diagnostic companies are active in diverse jurisdictions and business cultures. Thus they are quite vulnerable to internal and external deviance. For many years the Eurofins Group has been escaping scandals which plague others in the laboratory sector. A number of ethics rules and behavioural codes are designed to ensure compliance. But is on paper enough? How does the company enforce compliance and prevent corruptive activities? Hugues Vaussy, Director of Group Finance with global responsibilities for Insurance and Risk Management, Investor Relations, as well as capital market transactions answered B2Bioworld's questions.

If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Read Now - Please select your license (Prices incl. 7% VAT)
8 pages free of advertisement

Article free of advertisement

Full Company License enquire here

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Corporate Compliance: Training the paper tiger to purr, show its teeth, or jump on
Michael Schulz, at the time CFO and Compliance Officer of Bayer CropScience describes the workings of the system

Philanthropy re-visited: Merck’s focus on Africa
Stefan Oschmann, CEO and Chairman of the Executive Board Merck KGaA in an unplugged enquiry by B2Bioworld

Roche Ethiopia: Build-up of an emerging market

Eurofins helps Pasteur de Lille out of the doldrums
Prospects of IPL’s analytical services business

REACH in Practice
Richard Taylor, Global Technical Manager with SGS S.A. (Genève) takes biofuels and lubricity agents as examples.

Legal but not legitimate: Profit shifting via corporate tax

No Mercy with Violators of Corporate Compliance
Rüdiger Scheitza, Former Member of the Board Bayer CropScience, and Labour Director

Adhering to Values Pays Off
Novartis and its Focus on Emerging Markets

OECD: Brazil needs to improve greater integrity in public service

Abengoa and the renewable energies industry: Some expectations were very aggressive…
Christopher Standlee, Vice-President Global Affairs for Abengoa Bioenergy US

De-mystifying Corruption: Identifying, Sanctioning, Monitoring, Preventing